Comparative incidence of cancer in HIV-AIDS patients and transplant recipients

Cobucci, Ricardo Ney; Saconato, Humberto; Lima, Paulo Henrique; Rodrigues, Hugo Marcus; Prudêncio, Tardelli Lapaz; Eleutério, José; Giraldo, Paulo César; Gonçalves, Ana Katherine

doi:10.1016/j.canep.2011.12.002

Cited by 38 publications

(14 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a similar pattern of incidence of HPV-related cancers emerged from studies of transplant patients[32,33]. Transplant patients have generally different lifestyle exposures than HIV patients, but both groups have immune deficiency.…”

Section: Hpv Biology and Oncogenesismentioning

confidence: 82%

Human papillomavirus and gastrointestinal cancer: A review

Bucchi¹,

Stracci²,

Buonora³

et al. 2016

WJG

View full text Add to dashboard Cite

Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide. Exposure to HPV is very common, and an estimated 65%-100% of sexually active adults are exposed to HPV in their lifetime. The majority of HPV infections are asymptomatic, but there is a 10% chance that individuals will develop a persistent infection and have an increased risk of developing a carcinoma. The International Agency for Research on Cancer has found that the following cancer sites have a strong causal relationship with HPV: cervix uteri, penis, vulva, vagina, anus and oropharynx, including the base of the tongue and the tonsils. However, studies of the aetiological role of HPV in colorectal and esophageal malignancies have conflicting results. The aim of this review was to organize recent evidence and issues about the association between HPV infection and gastrointestinal tumours with a focus on esophageal, colorectal and anal cancers. The ultimate goal was to highlight possible implications for prognosis and prevention.

show abstract

Section: Hpv Biology and Oncogenesismentioning

confidence: 82%

Human papillomavirus and gastrointestinal cancer: A review

Bucchi¹,

Stracci²,

Buonora³

et al. 2016

WJG

View full text Add to dashboard Cite

show abstract

“…(8, 9) Immunosuppression is also a key cofactor, with elevated skin cancer risk in both OTR receiving immunosuppressive medications to prevent graft rejection and HIV/AIDS patients. (10, 11) Organ transplant registry studies have demonstrated a dose-response relationship between years of immunosuppression post-transplant and elevated skin cancer risk. (12–14) Longer duration of induced immunosuppression post-transplant necessarily results in not just years of a depressed immune response but also a longer duration of exposure to potentially carcinogenic transplant-related medications.…”

Section: Introductionmentioning

confidence: 99%

Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort

Coghill

Johnson

Berg

et al. 2016

American Journal of Transplantation

View full text Add to dashboard Cite

Organ transplant recipients (OTR) have a substantially elevated risk of squamous cell skin carcinoma (SCSC), largely attributed to immunosuppressive medications used to prevent graft rejection, although data to support the role of newer drugs on SCSC risk are sparse. We investigated the association between immunosuppressive medications and SCSC risk among cardiac and renal transplant recipients in the SCOT cohort study. Incident cases were ascertained through medical record review after self-report of skin biopsy (N=170). Controls without SCSC (N=324) were matched to cases on: gender, age, race, transplant year, hospital, donor type, organ transplanted, and time between transplant and interview. Conditional logistic regression was used to evaluate the association between specific medications and SCSC. Users of the older anti-metabolite azathioprine were more than twice as likely to develop SCSC (OR=2.69; 95%CI 1.23–5.84) compared to non-users. In contrast, the newer anti-metabolite preparations (i.e., mycophenolic acid [MPA]) were associated with lower SCSC risk (OR=0.43; 95%CI 0.27–0.66). This inverse association between MPA and SCSC persisted among OTR with no history of azathioprine use, even after adjustment for simultaneous use of the calcineurin inhibitor tacrolimus (OR=0.50; 95%CI 0.31–0.81). Our data suggest that the increased risk of SCSC historically associated with azathioprine is not seen in OTR prescribed newer regimens, including MPA and tacrolimus.

show abstract

“…Thus, although AIDS patients are at increased risk for some cancers due to their immune state [61], it has been a surprise to many that lentiviral vectors based on the HIV-1 LTRs have not been found in preclinical and clinical studies to have associated adverse events stemming from either activation, inactivation, and/or alteration of splicing of endogenous genes [62, 63]. Although the absence of cancers and leukemias following integrations of lentiviruses (including those with AIDS) might be due to the ability of the lentiviral vectors to infect non-dividing cells for therapeutic benefit [64] or their selection of a different set of genetic loci for integration [38, 39, 65–67] even though the integration of both is directed into outward-facing major grooves on nucleosomal DNA [68].…”

Section: Introductionmentioning

confidence: 99%

Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy

Hackett¹,

Largaespada²,

Switzer³

et al. 2013

Translational Research

View full text Add to dashboard Cite

Investigational therapy can be successfully undertaken using viral- and non-viral-mediated ex vivo gene transfer. Indeed, recent clinical trials have established the potential for genetically modified T cells to improve and restore health. Recently the Sleeping Beauty (SB) transposon/transposase system has been applied in clinical trials to stably insert a chimeric antigen receptor (CAR) to redirect T-cell specificity. We discuss the context in which the SB system can be harnessed for gene therapy and describe the human application of SB-modified CAR+ T cells. We have focused on theoretical issues relating to insertional mutagenesis in the context of human genomes that are naturally subjected to remobilization of transposons and the experimental evidence over the last decade of employing SB transposons for defining genes that induce cancer. These findings are put into the context of the use of SB transposons in the treatment of human disease.

show abstract

Comparative incidence of cancer in HIV-AIDS patients and transplant recipients

Cited by 38 publications

References 35 publications

Human papillomavirus and gastrointestinal cancer: A review

Human papillomavirus and gastrointestinal cancer: A review

Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort

Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy

Contact Info

Product

Resources

About